Aktienanalyse zu Cardiol Therapeutics Inc (CRDL)CRDLCardiol Therapeutics Inc

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Currently, Cardiol Therapeutics Inc (CRDL) is not a strong buy due to its low current price of $1.04 and an RSI of 21.3, indicating oversold conditions. However, the potential upside is significant with an analyst price target of $11, suggesting a potential upside of over 950%. The main risk is the company's ongoing losses, with a net income of -10,818,589 CAD in Q1 2026, which raises concerns about its financial stability.